Loading stock data…
LNSR
$5.56-0.05 (-0.89%)
After Hours$5.24-0.32 (-5.76%)· Last close May 4
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LENSAR, Inc. in the Healthcare sector is trading at $5.56. The stock is currently near its 52-week low of $5.06, remaining 48.9% below its 200-day moving average. Technical signals show neutral RSI of 41 and bullish MACD crossover, explaining why LNSR maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.56
Potential Upside
5%
Whystock Fair Value$5.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$64.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
81.96%
Volume
Today's trading volume
48,298
Recent News
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential
The updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential upside. Supporters connect this $10 mark to their view that ALLY System adoption can return to patterns seen before the Alcon deal was announced, while skeptics question whether that setup already bakes in optimistic execution. As you read on, you will see how both the bullish...
Cedar Grove Capital Management’s Views on LENSAR (LNSR)
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here. Cedar Grove Capital Management’s Multi-Strategy Composite posted a -23.0% net return since inception, compared to -5.6% for the Russell 2000, -5.9% for the Russell Microcap, and -5.5% for the S&P 500. […]
How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target Reset
The reset in LENSAR’s fair value price target from $12.50 to $8.50 puts the recent update to the story front and center for anyone tracking the stock. Analysts are weighing how this new $8.50 level lines up with at least one $10 target, especially after the failed Alcon transaction and renewed focus on the ALLY System. Read on to see how to interpret these shifting targets and follow the evolving narrative around expectations and valuation. Stay updated as the Fair Value for LENSAR shifts by...
LENSAR Inc (LNSR) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
Despite a dip in quarterly revenue, LENSAR Inc (LNSR) reports robust procedure volume growth and a significant increase in its ALLY system installed base.
LENSAR, Inc. Q4 2025 Earnings Call Summary
Moby summary of LENSAR, Inc.'s Q4 2025 earnings call